Xencor, Inc. (XNCR) Given Consensus Rating of “Hold” by Brokerages
Xencor, Inc. (NASDAQ:XNCR) has been given an average recommendation of “Hold” by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $29.40.
A number of research firms have recently commented on XNCR. Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Wedbush reaffirmed an “outperform” rating and set a $29.00 target price on shares of Xencor in a research report on Wednesday, May 10th. Canaccord Genuity reaffirmed a “buy” rating and set a $36.00 target price on shares of Xencor in a research report on Tuesday, August 8th. Finally, BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th.
Xencor (XNCR) traded down 2.01% during midday trading on Friday, reaching $19.94. 202,717 shares of the company were exchanged. The firm’s market cap is $935.70 million. The firm’s 50-day moving average is $22.56 and its 200-day moving average is $23.00. Xencor has a one year low of $18.45 and a one year high of $29.38.
Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The company had revenue of $13.34 million for the quarter, compared to analyst estimates of $8.15 million. On average, equities analysts expect that Xencor will post ($1.17) EPS for the current fiscal year.
In other news, Director Bruce L. A. Carter sold 2,366 shares of the business’s stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $22.00, for a total value of $52,052.00. Following the sale, the director now owns 68,578 shares in the company, valued at approximately $1,508,716. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce L. A. Carter sold 12,400 shares of the business’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $22.19, for a total transaction of $275,156.00. Following the completion of the sale, the director now owns 83,344 shares in the company, valued at approximately $1,849,403.36. The disclosure for this sale can be found here. In the last three months, insiders acquired 182,035 shares of company stock worth $3,728,456 and sold 34,766 shares worth $739,408. Insiders own 4.03% of the company’s stock.
Several large investors have recently modified their holdings of XNCR. Equitec Specialists LLC purchased a new stake in shares of Xencor during the second quarter valued at approximately $116,000. SG Americas Securities LLC increased its stake in shares of Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,252 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares in the last quarter. Airain ltd purchased a new stake in shares of Xencor during the first quarter valued at approximately $213,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Xencor during the second quarter valued at approximately $224,000. Institutional investors own 73.53% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/19/xencor-inc-xncr-given-consensus-rating-of-hold-by-brokerages.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.